Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EBT Margin for 10 consecutive years, with 61.6% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 1907.0% to 61.6% in Q4 2025 year-over-year; TTM through Dec 2025 was 84.84%, a 1641.0% increase, with the full-year FY2025 number at 84.84%, up 1641.0% from a year prior.
  • EBT Margin was 61.6% for Q4 2025 at Ultragenyx Pharmaceutical, up from 112.26% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 61.6% in Q4 2025 to a low of 263.3% in Q3 2022.
  • A 5-year average of 131.85% and a median of 138.41% in 2021 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 19010bps in 2021; the steepest drop was -18193bps in 2021.
  • Ultragenyx Pharmaceutical's EBT Margin stood at 149.63% in 2021, then grew by 1bps to 148.32% in 2022, then surged by 32bps to 100.22% in 2023, then increased by 20bps to 80.67% in 2024, then rose by 24bps to 61.6% in 2025.
  • Per Business Quant, the three most recent readings for RARE's EBT Margin are 61.6% (Q4 2025), 112.26% (Q3 2025), and 68.47% (Q2 2025).